氯吡格雷联合辛伐他汀治疗CHD合并TIA的疗效分析

Treating CHD plus TIA with clopidogrel and simvastatin

目的:探讨氯吡格雷联合辛伐他汀治疗冠心病(CHD)合并短暂性脑缺血发作(TIA)的疗效。方法:根据治疗方案将2011年1月-2013年4月我院收治的107例CHD合并TIA患者分为对照组与观察组。观察组55例患者,接受氯吡格雷联合辛伐他汀治疗,对照组52例患者,接受氯吡格雷治疗,对比分析两组患者的疗效。结果:1治疗前,两组患者甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)相比差异无统计学意义(P>0.05)。治疗后,观察组TG、TC、LDL-C显著低于对照组,HDL-C显著高于对照组,差异有统计学意义(P<0.05)。2观察组治疗效果显著优于对照组,差异有统计学意义(P<0.05)。结论:氯吡格雷联合辛伐他汀治疗CHD合并TIA的疗效确切,值得临床推广应用。

Objective： To investigate treating CHD plus TIA with clopidogrel and simvastatin. Methods：107 cases of CHD plus TIA patients were divided into the control group and the observed group. 55 patients in the observed group, received clopidogrel and simvastatin therapy; 52 patients in the control group, treated with clopidogrel. Results： After treatment, in the observed group TG, TC, LDL-C was significantly lower than the control group; HDL-C was significantly higher; the difference was statistically significant （P〈0.05）. Clinical efficacy was significantly better than the control group （P〈0.05）. Conclusion： The efficacy of clopidogrel plus simvastatin was good at CHD and TIA.